Drug Profile
Insulin/pramlintide - Amylin/JDRF
Alternative Names: Pramlintide/insulinLatest Information Update: 28 Sep 2018
Price :
$50
*
At a glance
- Originator Amylin Pharmaceuticals; JDRF
- Developer AstraZeneca; JDRF
- Class Insulins; Macromolecular substances; Pancreatic hormones; Proteins
- Mechanism of Action Amylin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in USA (SC, Infusion)
- 01 Aug 2016 AstraZeneca completes a phase I trial for Type-1 diabetes mellitus in USA (NCT02500979)
- 08 Aug 2012 Amylin Pharmaceuticals has been acquired by Bristol-Myers Squibb